SPSilvia Pontis

Silvia Pontis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Silvia Pontis has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Comparative Assessment of the Antifibrotic Effect of Nintedanib Administered via a Medicated Diet or Oral Gavage in a Rat Model of Bleomycin-Induced Pulmonary Fibrosis

    by Vanessa Pitozzi, Paola Caruso, Silvia Pontis, Francesca Ruscitti, Maria Gloria Pittelli, Giancarlo Aquino, Roberta Volta, Alice Pappani, Mariarosaria Barrea, Federico Quaini, et al.

    Idiopathic pulmonary fibrosis (IPF) remains a progressive and fatal disease despite major advances in antifibrotic therapy. Pirfenidone and nintedanib slow lung function decline, and the PDE4B inhibitor nerandomilast and treprostinil have recently shown promise as next-generation treatments. However, current therapies neither halt nor reverse disease progression, and tolerability issues often limit adherence. We compared the antifibrotic activity and plasma levels of nintedanib administered by either oral gavage or dietary supplementation in a rat model of pulmonary fibrosis. Male Sprague-Dawley rats received intratracheal bleomycin (1 U/kg) on days 0 and 4. From day 7 to day 28, animals were treated with nintedanib (100 mg/kg/day) by either oral gavage or medicated chow. Lung weight, fibrosis biomarkers (procollagen-I, metalloproteinase-7 or MMP7, WNT1-inducible signaling pathway protein or WISP-1), epithelial injury marker KL-6, target engagement biomarkers (Fibroblast Growth Factor 2 or FGF-2, Vascular Endothelial Growth Factor or VEGF), plasma drug levels, and histological fibrosis scores were evaluated. Both administration regimens significantly reduced procollagen-I, WISP-1 and KL-6, and histological fibrosis scores. Oral gavage produced approximately fourfold-higher peak plasma concentrations of nintedanib 30 min after dosing, whereas dietary administration resulted in lower, more stable plasma levels with reduced variability while resulting in comparable antifibrotic efficacy. In conclusion, nintedanib retained robust antifibrotic activity when administered via dietary supplementation despite lower, but continuous, active plasma concentrations. Collectively, these findings indicate that optimizing drug delivery and absorption kinetics may achieve sustained therapeutic efficacy while reducing unnecessary exposure to supratherapeutic concentrations, thereby potentially improving tolerability.

  • Open Access

    From Airways to Arteries: Dissecting the Inflammatory Mechanisms of Pulmonary Vascular Remodeling in a Murine Model of Chronic Airway Inflammation

    by Silvia Siragusa, Elena Tantillo, Silvia Parolo, Gloria Modafferi, Maria Laura Faietti, Giulia Natali, Paola Caruso, Sofia Beghi, Silvia Cantoni, Mary Delli Carpini, et al.

    Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive, incurable condition marked by irreversible airflow limitation and systemic inflammation. Cardiovascular comorbidities, particularly pulmonary hypertension (PH), exacerbate disease severity. While cigarette smoke is a well-known trigger, non-smoking-related inflammatory pathways remain underexplored. This study investigates vascular remodeling in a murine model of inflammation induced by chronic exposure to house dust mite Farinae (HDM). Methods: Female C57BL/6 mice were sensitized with HDM in Freund’s Complete Adjuvant and challenged intranasally with HDM for six weeks. Lung inflammation, mucus hypersecretion, and vascular remodeling were evaluated via BAL, histology, immunofluorescence, echocardiography, gene expression, proteomics, and FlexiVent pulmonary function tests (FlexiVent system). Results: HDM exposure induced a mixed inflammatory response, with elevated neutrophils, monocytes, and lymphocytes in BALF. Mucus hyperproduction (increase in MUC5AC/MUC5B) and impaired lung function (reduced FEV0.1/FVC) were observed. Vascular remodeling was evidenced by increased wall thickness, α-SMA expression, and collagen deposition. Proteomic analysis revealed dysregulation of endothelial markers and protease/antiprotease imbalance. HIF1-α was significantly upregulated in lung tissue and correlated with vascular and epithelial remodeling. Conclusions: Chronic HDM exposure in mice recapitulates key features observed in subsets of COPD and PH, including inflammation-driven airway and vascular remodeling. HIF1-α emerges as a central regulator, linking hypoxia to structural changes. This model offers insights into the effect of non-smoking-related inflammatory pathways on bronchial and vascular remodeling that are potentially relevant for subgroups of COPD patients and highlights HIF1-α as a potential therapeutic target.

  • Open Access

    Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model

    by Martina Bonatti, Vanessa Pitozzi, Paola Caruso, Silvia Pontis, Maria Gloria Pittelli, Caterina Frati, Denise Madeddu, Federico Quaini, Costanza Anna Maria Lagrasta, Ilaria Minato, et al.

    Background and Purpose: Idiopathic pulmonary fibrosis is a progressive lung disease with high clinical need. In this context, nintedanib significantly reduces acute exacerbation risk, however its comprehensive effect on fibrosis remains unclear. This study aims to evaluate nintedanib transcriptomic impact on lung fibrosis to uncover molecular signatures for new therapeutics. Experimental Approach: Lung fibrosis was induced by two intratracheal bleomycin administrations. Nintedanib was administered orally daily for 3 weeks. Histological and transcriptome data were obtained using automated fibrosis quantification, Ashcroft Score and RNA sequencing, respectively. Correlation network analysis (WGCNA) modules were identified and examined by cell and pathway enrichment analysis. Lipid peroxidation was tested using malondialdehyde. Key Results: Nintedanib reduced fibrotic lesions by ~15%, decreased severe Ashcroft scores , . WGCNA identified two clusters correlated with histological parameters, where nintedanib counter‐regulates gene expression. One cluster was associated with mesenchymal cells (fibroblast and smooth muscle; −log p‐val > 4.45), energy production, cellular metabolism and extracellular matrix‐related pathways (−log q‐val > 11). The second cluster, enriched predominantly in resident macrophages (−log p‐val > 12.36), was related to lysosomal activity and lipid metabolism (−log q‐val > 21). Nintedanib inhibited bleomycin elevated malondialdehyde levels. Conclusions and Implications: The study highlighted two distinct protective effects of nintedanib on lung fibrosis. One well‐known on mesenchymal cells and matrix‐related components. Plus, one related to the involvement of the pneumocyte–macrophage paracrine lipid axis, where oxidized lipids alter macrophage activities, leading to the formation of lipid‐filled macrophages. This may open new research directions.

  • Open Access

    In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model

    by Vanessa Pitozzi, Paola Lorenza Caruso, Silvia Pontis, Barbara Pioselli, Francesca Ruscitti, Maria Gloria Pittelli, Costanza A. M. Lagrasta, Federico Quaini, Antonella Maria Nogara, Giancarlo Aquino, et al.

    Nintedanib is an anti-fibrotic medication endowed with a multi-kinase inhibitor profile and approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Nintedanib is believed to inhibit mainly Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF) receptor kinases. The main objective was to identify potential tissue and/or circulating biomarkers to demonstrate Nintedanib’s target engagement and support its in vivo pharmacodynamic activity, consistent with its proposed mechanism(s) of action. In four independent experiments of bleomycin (BLM)-induced lung fibrosis model in rats, animals received Nintedanib (oral, 100 mg/kg/day) from day 7 post-BLM for 3 weeks. As expected, Nintedanib significantly reduced lung weight, the levels of lung fibrotic markers, and fibrotic areas. Moreover, Nintedanib-treated animals expressed lower levels of FGF2 in lung homogenates and higher plasma and lung levels of VEGF (≥3-fold, p < 0.05) compared to control animals. Lung proteomic analysis revealed the inhibition of receptor tyrosine kinases signaling in Nintedanib-treated animals. Circulating and lung levels of Nintedanib confirmed an optimal tissue distribution in the rat, consistent with the data reported for humans. Although VEGF ligand levels are elevated in the lungs of Nintedanib-treated animals, the VEGF signaling pathway remained functionally downregulated, strongly suggesting compensatory VEGF feedback delivery to its receptor blockade by Nintedanib. In summary, based on the present experimental findings in rats and supporting clinical preliminary evidence, increased VEGF levels can be reasonably considered an indicator of target engagement for Nintedanib and potentially for other VEGF modulators.


  • Open Access

    Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model

    by Martina Bonatti, Vanessa Pitozzi, Paola Caruso, Silvia Pontis, Maria Gloria Pittelli, Caterina Frati, Denise Madeddu, Federico Quaini, Costanza Anna Maria Lagrasta, Ilaria Minato, et al.

    INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible lung disease with a poor prognosis. While pirfenidone and nintedanib offer some benefits, they cannot cure IPF. Nintedanib inhibits various proliferative pathways and has antifibrotic effects, but its molecular mechanisms and impact on the lung transcriptome in vivo remain unclear. This study aims to evaluate nintedanib’s transcriptomic profile in a rat model of bleomycin-induced lung fibrosis. METHODOLOGY/PRINCIPAL FINDINGS: Lung fibrosis was induced by two intratracheal administrations of bleomycin. Nintedanib protocol included three weeks of daily oral treatments beginning seven days after the first bleomycin dose. Left lungs were processed for histological evaluation using an automated fibrosis quantification system and the Ashcroft Score, while the right lungs were used for RNA sequencing to conduct differential expression and correlation network analysis (WGCNA). WGCNA modules were examined by cell and pathway enrichment analysis. Lipid peroxidation was assessed through the measurement of malondialdehyde in right lung lysates. Bleomycin induced significant fibrotic lesions, as confirmed by the histological evaluations. Nintedanib reduced fibrotic lesion size by about 15% and decreased severe Ashcroft scores. When compared to controls, the number of differentially expressed genes decreased from over 2000 to barely more than 400 after nintedanib treatment. WGCNA identified two gene clusters correlated to histological parameters, with nintedanib-treated animals showing gene expression levels similar to control animals. One cluster was associated with mesenchymal cells and extracellular matrix-related pathways, in line with the known anti-fibrotic effect of nintedanib. The second cluster, involving principally macrophages, was related to lipid metabolism, potentially uncovering a new mechanistic role of nintedanib in modulating lung fibrosis. CONCLUSIONS/SIGNIFICANCE: The mechanisms involving macrophages and lipid metabolism, influenced by nintedanib in this study, may open new research directions to better inquire the role of this cellular type in tissue repair and pathological lung fibrosis.


  • Open Access

    Investigation of Aberrant Basaloid Cells in a Rat Model of Lung Fibrosis

    by Emanuela Bocchi, Vanessa Pitozzi, Silvia Pontis, Paola L. Caruso, Sofia Beghi, Mariafrancesca Caputi, Marcello Trevisani, Francesca Ruscitti

    Background: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) whose cause and pathogenesis are not yet well understood. Until now, no animal model of lung fibrosis succeeds in recapitulating all IPF features, thus the use of different rodent models is essential for the evaluation and development of new effective pharmacological treatments. Recently, the alveolar epithelial dysfunction has been emphasized in the etiopathogenesis context of IPF. Remarkably, the role of an aberrant basaloid cell type, primarily found in humans and confirmed in mice, seems to be crucial in the establishment and progression of the disease/model. Our work aimed to characterize for the first time this cell population in a rat model of lung fibrosis induced by a double bleomycin (BLM) administration, demonstrating the translational value of the model and its potential use in the testing of effective new drugs. Methods: Rats received an intratracheal BLM administration at day 0 and 4. Animals were sacrificed 21 and 28 days post-BLM. The fibrosis evaluation was carried out through histological (Ashcroft score and automatic image analysis) and immunoenzymatic analysis. Immunofluorescence was used for the characterization of the aberrant basaloid cells markers. Results: Lung histology revealed an increase in severe grades of Ashcroft scores and areas of fibrosis, resulting in a rise of collagen deposition at both the analyzed time-points. Immunofluorescence staining indicated the presence of KRT8+ cells in bronchial epithelial cells from both controls (saline, SAL) and BLM-treated animals. Interesting, KRT8+ cells were found exclusively in the fibrotic parenchyma (confirmed by the alpha-smooth muscle actin (α-SMA) staining for myofibroblasts) of BLM-treated animals. Moreover, KRT8+ cells co-expressed markers as Prosurfactant protein C (Pro-SPC) and Vimentin, suggesting their intermediate state potentially originating from alveolar type II (AT2) cells, and participating to the abnormal epithelial–mesenchymal crosstalk. Conclusion: Previous preclinical studies demonstrated the presence of KRT8+ aberrant basaloid-like cells in murine models of lung fibrosis. This work investigated the same cell population in a different rodent (the rat) model of lung fibrosis triggered by a double administration of BLM. Our results provided a further confirmation that, in rats, the intratracheal administration of BLM induced the appearance of a population of cells compatible with the KRT8+ alveolar differentiation intermediate (ADI) cells, as described previously in the mouse. This piece of work enforces previous evidence and further support the use of a rat model of BLM resembling the alveolar epithelial dysfunction to evaluate new clinical candidates for development in IPF.


  • Open Access

    The role of pulmonary vascular endothelium in chronic obstructive pulmonary disease (COPD): Does endothelium play a role in the onset and progression of COPD?

    by Silvia Siragusa, Giulia Natali, Antonella Maria Nogara, Marcello Trevisani, Costanza Anna Maria Lagrasta, Silvia Pontis

    Chronic obstructive pulmonary disease (COPD) is an inflammatory lung pathology characterized by persistent airflow limitation and is the third leading cause of death globally. COPD pathophysiology includes both environmental and host risk factors and the presence of comorbidities contributes to its harmful outcome. Cardiovascular disease (CVD) is closely related to COPD and their coexistence is associated with worse outcomes than either condition alone. COPD impairs the cardiovascular system favoring mostly endothelial dysfunction that is a significant COPD prognostic factor at different stages of the disease. The mechanisms promoting endothelial dysfunction in the systemic and/or pulmonary circulation of COPD patients are different and include systemic inflammation, alteration of adhesion and pro-inflammatory molecules, oxidative stress, cellular senescence, and apoptosis. Nevertheless, the role of endothelium in the onset and progression of COPD and CVD is not yet fully understood. Hence, the purpose of this narrative review is to analyze the literature and provide evidence supporting the importance of endothelial dysfunction in COPD.


  • Modelling IPF-associated chronic cough: role for oxidative stress?

    by Jonathan Miles, James W Pinkerton, Sara J Bonvini, Eric Dubuis, Michael A Wortley, Silvia Pontis, Marcello Trevisani, Gino Villetti, Riccardo Patacchini, Philip L Molyneaux, et al.

    Introduction: Chronic cough is a key symptom that plagues the lives of IPF patients, indeed, it is often the reason the disease is initially diagnosed. The aim of this project was to develop a pre-clinical model of IPF-associated cough and compare the mediator profiles with clinical samples, to aid in the search for effective treatments. Methods: Male guinea pigs (around 325g) were intratracheally dosed with vehicle (saline) or bleomycin (6 USP/kg) and coughs were quantified through manual observation of in-cage video footage, by watching 4.5 hours a day, for 3 weeks. Lung tissue, bronchoalveolar lavage fluid (BALF) and blood was harvested from a parallel group of animals. These were used to assess the extent of fibrosis and measure mediator production (e.g. a marker of oxidative stress: 8-isoprostane). Human BALF was obtained from IPF patients and healthy controls. Results: Spontaneous coughing was recorded in guinea pigs given bleomycin, which was associated with an increase in lung fibrosis and BALF 8-isoprostane (a marker of oxidative stress). We noted similar increases in BALF 8-isoprostane levels in the clinical samples. Conclusions: We have developed a preclinical model to aid in the search for a treatment for IPF-associated coughing. Furthermore, initial data suggests that an increase in oxidative burden (a known trigger of coughing) could be an attractive target.

  • Automated histological image analysis for the assessment of bleomycin-induced pulmonary fibrosis in rodents

    by Silvia Pontis, Fabio Bignami, Daniela Miglietta, Vanessa Pitozzi, Paola Caruso, Maria Gloria Pittelli, Martina Bonatti, Gino Villetti, Maurizio Civelli, Marcello Trevisani

    Introduction: Bleomycin (BLM)-induced lung fibrosis is currently the main pre-clinical rodent model in use for the screening of potential therapeutics in Idiopathic Pulmonary Fibrosis (IPF). Typically, histological lung fibrosis scoring is observer-dependent and consequently subject to variability, precluding comparative studies between different laboratories. Thus, a reliable and observer-independent quantification of lung fibrosis is needed. Aims and Objectives: We developed automated image Analysis Protocol Packages (APPs) by using a flexible software (Visiopharm) to quantify fibrotic lung lesions and collagen deposition in digital images of lung sections from mice and rats treated with a double intratracheal administration of BLM. Methods: The first APP was set-up to automatically quantify the fibrotic tissue, detecting accumulation of connective tissue, excess of collagen deposition and cellular hyperproliferation in Masson’s trichrome stained lung sections. The second APP was developed to specifically quantify collagen deposition on Mallory-Azan’s trichrome stained slices. Results: We confirmed a significant increase in BLM-induced lung fibrosis and collagen deposition in both mice and rats at day 14 and 21 post-BLM, respectively, with a significant correlation with the Ashcroft score. Moreover, the antifibrotic effect by oral Nintedanib (60 mg/kg/day in mice and 100 mg/kg/day in rats from day 7 post-BLM) was clearly established. Conclusions: Overall, these data describe a novel observer-independent measure of BLM-induced lung fibrosis in rodents, which could be beneficial for the evaluation of potential preclinical drugs in the lung fibrosis field.


  • Novel activity-based probes for N-acylethanolamine acid amidase

    by Rita Petracca, Elisa Romeo, Marc P. Baggelaar, Marta Artola, Silvia Pontis, Stefano Ponzano, Herman S. Overkleeft, Mario van der Stelt, Daniele Piomelli

    The cysteine hydrolase, N-acylethanolamine acid amidase (NAAA) is a promising target for analgesic and anti-inflammatory drugs. Here, we describe the development of two unprecedented NAAA-reactive activity-based probes as research tools for application in the discovery of new inhibitors and for the in-depth characterization of NAAA in its cellular environment.